Citation

Abe K, Momo K, Oto Y, Kida M, Iwakiri T, Tanaka K, Sasaki T. Clin. Case Rep. 2023; 11(1): e6748.

Copyright

(Copyright © 2023, John Wiley and Sons)

DOI

10.1002/ccr3.6748

PMID

36698524

PMCID

PMC9860198

Abstract

The negative effects of anticoagulants are well-known in patients with renal impairment, drug-drug interaction, lower physical conditions, and multiple comorbidities. We highlight that even in patients with controllable multiple risks for rivaroxaban use, add-on inevitable risks will lead to negative effects greater than those expected.

Language: en

Keywords

drug–drug interaction; erythromycin; renal dysfunction; rivaroxaban